TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity

TS-047118 — Analogues of verticillin with significantly improved drug-like properties, including increased solubility, absorption, and stability, while maintaining similar anticancer potency as the verticillin parent compounds.

TS-037724 — Researchers at The Ohio State University have discovered Compound 13, a patent protected, orally bioavailable and brain penetrant Mps1/TTK inhibitor that exhibits single agent tumor growth inhibition in a murine xenograft model of human triple negative breast cancer upon daily administration.

TS-037721 — A group of potential antitumor arylnapthalene lactone derivatives, which may be developed as novel anticancer and immunostimulant agents.

TS-037671 — Novel non-peptidomimetic molecules for use as anti-cancer inhibitors of signal transducer and activator of transcription 3.

TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.

TS-037569 — The constant activation of Signal Transducer and Activator of Transcription 3 (STAT3) is frequently detected in many cancer patients with advanced diseases. About 80% of all cancers overexpress STAT3, including solid tumors, lymphoma, and leukemia. Constant activation of STAT3 activities in nonmal…

TS-037293 — Multiple novel series of small molecule inhibitors of DNA gyrase and topoisomerase IV, including a lead anti-MRSA molecule with in vivo efficacy and a favorable in vitro safety profile. The technology offers potential options for Gram-positive pathogens (including MRSA, VRE, and Streptococcus pneumoniae), Gram-negative bacteria such as Neisseria gonorrhoeae and Acinetobacter baumannii, and mycobacteria (including Mycobacterium tuberculosis and non-tuberculous mycobacteria).

TS-036754 — This technology aims to optimize the CRISPR-Cpf1 complex by chemically modifying the crRNA nucleotides and engineering crRNA sequences.

TS-032141 — The guide RNA is chemically modified to improve Cpf1 nuclease activity, reduce toxicity, decrease off-target effects, and increase stability.